Short answer
Cardiff Oncology, Inc. (CRDF) filed its Q2 2026 10-Q quarterly report on Aug 11, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $104,000 (down 14.0% year over year) with net income of −$9M.
Q2 2026 key financials · XBRL
- Revenue
- $104,000
- −14.0% YoY · +153.7% QoQ
- Net income
- −$9M
- +33.8% YoY · +25.2% QoQ
- Operating margin
- -9245.2%
- EPS (diluted)
- −$0.14
- +33.3% YoY · +22.2% QoQ
Source: XBRL data from the Cardiff Oncology, Inc. (CRDF) Q2 2026 10-Q on SEC EDGAR. USD.
Cardiff Oncology, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New litigation risk: Cardiff sued NMS over alleged wrongful termination of the onvansertib license agreement; NMS filed counterclaims
- Most material business risk: Validated termination could eliminate exclusive rights to onvansertib intellectual property
- Regulatory or legal risk: Failure to obtain preliminary injunctive relief could permit NMS to enforce termination during litigation
- Operational risk: Litigation may divert senior-management resources from strategic priorities for multiple years
- Financial risk: Pending litigation could restrict access to equity or debt financing on favorable terms
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Cardiff Oncology, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.